Come up with a name for your new list and we'll add to it:
Oryzon Genomics raised a round of funding on May 18, 2015. Investors include
Alzheimer's Drug Discovery Foundation.
Oryzon Genomics is a privately held, clinical stage biopharmaceutical company. Its LSD1 program is covered by 18 patent families and has rendered one compound in clinical trials and another one to ent…